• Explore /
  • Poster
  • / Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Etctn 10388: A phase I trial of triapine and lutetium Lu 177 dotatate in well-differentiated somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).

Abstract Poster

Authors

null

Aman Chauhan

University of Kentucky, Division of Medical Oncology, Lexington, KY

Aman Chauhan , Charles Kunos , Riham El Khouli , Jill Kolesar , Heidi Weiss , William Edgar Carson III, Mark B Evers , Mark S. Kidd , Jan Hendrik Beumer , Susanne M. Arnold , Elise C. Kohn , Lowell Brian Anthony

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Neuroendocrine/Carcinoid

Clinical Trial Registration Number

04234568

Citation

J Clin Oncol 38: 2020 (suppl; abstr TPS4660)

DOI

10.1200/JCO.2020.38.15_suppl.TPS4660

Abstract #

TPS4660

Poster Bd #

268

Abstract Disclosures

Similar Posters

First Author: Aman Chauhan

First Author: Aman Chauhan

First Author: Aman Chauhan

First Author: Rohini Sharma